Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEMBRACA: Pembrolizumab + Carboplatin in BRCA-related Metastatic Breast Cancer
NCT03732391Phase 2Completed
- Start
- Dec 2018
- Primary completion
- Jun 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in breast cancer. Started Dec 2018; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03732391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03732391.